Trial record 1 of 1 for:    gel-the-nec
Previous Study | Return to List | Next Study

Registry for Study of Coils in Intracranial Aneurysms (Gel-the-nec)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Abbott
Albany Medical College
Asan Medical Center
Baylor University
Bronson Methodist Hospital
Capital Health, Canada
The Cleveland Clinic
Dalhousie University
First Affiliated Hospital
Fudan University
Fort Sanders Regional Medical Center
JFK Medical Center, Florida
Kobe City Medical Center
Methodist Research Institute, Indianapolis
MUSC
Providence Health & Services
Scott and White Hospital & Clinic
Stony Brook University
Thomas Jefferson University
Royal University Hospital Foundation
University of California, Los Angeles
University of Florida
University of Maryland
University of Oklahoma
University of Southern California
Washington University School of Medicine
Information provided by (Responsible Party):
David F. Kallmes, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01000675
First received: October 22, 2009
Last updated: September 27, 2013
Last verified: September 2013

October 22, 2009
September 27, 2013
August 2009
September 2014   (final data collection date for primary outcome measure)
We will compare recanalization or recurrence rates observed in this prospective registry of HydroSoft coils used as finishing coils to historical series of aneurysms treated with bare platinum coils. [ Time Frame: 6 - 18 months post coiling ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01000675 on ClinicalTrials.gov Archive Site
HydroSoft embolic coil can be placed reliably in intracranial, saccular aneurysms, even late in the embolization procedure. [ Time Frame: 6 - 18 months post coiling ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Registry for Study of Coils in Intracranial Aneurysms
Gaining Efficacy Long Term: Hydrosoft, an Emerging, New, Embolic Coil (Gel-the-nec)

The current proposal describes a post-market, clinical registry of HydroSoft, aimed at gaining robust clinical data in a large set of patients to better define the advantages, and potentially, the disadvantages of the HydroSoft, and to inform future randomized trials.

Aim 1. (Primary Outcome) To test the hypothesis that HydroSoft coils lead to diminished rates of aneurysm recurrence relative to bare platinum coils. In order to test this hypothesis, we will compare recanalization or recurrence rates observed in this prospective registry of HydroSoft coils used as finishing coils to historical series of aneurysms treated with bare platinum coils. This registry is designed to achieve 80% power to detect a minimally clinically relevant difference in rates of recurrence between HydroSoft-treated aneurysms compared with bare platinum coils. Based on recent, prospective, randomized trials assessing both bare platinum coils and hydrogel-bearing coils with 25% and 15% recurrence rates, respectively, we predict a recurrence rate of 18% for HydroSoft treated aneurysms. Typically, a "minimally clinically relevant difference" is on the order of a 30% diminution in a given undesirable outcome. As such, the registry is well powered to detect this minimally clinically relevant difference (18% expected recurrence rate for HydroSoft treated coils versus 25% for the historical control group).

Aim 2. (Secondary Outcome 1) To test the hypothesis that the HydroSoft embolic coil can be placed reliably in intracranial, saccular aneurysms, even late in the embolization procedure. Success of this aim is defined as ease of placement of the HydroSoft device, without need for coil removal and subsequent "finishing" with a bare platinum coil.

Aim 3. (Secondary Outcome 2) To test the hypothesis that use of the HydroSoft embolic coil is associated with risks of thromboembolism similar to that with other coil types, on the order of 3-5% or less.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

All people with cerebral aneurysms between the ages of 21 and 90 that are treated with coils.

Cerebral Aneurysms
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
600
September 2015
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patient presenting with a ruptured or un-ruptured cerebral aneurysm appropriate for endovascular treatment as determined by the neurovascular team (neurosurgeon/neurointerventionist)
  2. Patient age: patients aged between 21 and 90 years will be eligible.
  3. Patient HUNT AND HESS Grade 0-3.
  4. Patient has given fully informed consent to endovascular coiling procedure or if patient cannot consent for themselves, appropriate written consent has been sought from their next of kin, or from appropriate power of attorney.
  5. Aneurysm 3-15mm in maximum diameter.
  6. Patient is willing and able to return for follow up angiography or MRA between 6-18 months.
  7. The patient has not been previously entered into this registry
  8. The aneurysm has not previously been treated (by coiling or clipping).

Exclusion Criteria:

  1. Inability to obtain informed consent.
  2. Medical or surgical comorbidity such that the patient's life expectancy is less than 1 year.
Both
21 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01000675
09-002933
No
David F. Kallmes, Mayo Clinic
Mayo Clinic
  • Abbott
  • Albany Medical College
  • Asan Medical Center
  • Baylor University
  • Bronson Methodist Hospital
  • Capital Health, Canada
  • The Cleveland Clinic
  • Dalhousie University
  • First Affiliated Hospital
  • Fudan University
  • Fort Sanders Regional Medical Center
  • JFK Medical Center, Florida
  • Kobe City Medical Center
  • Methodist Research Institute, Indianapolis
  • MUSC
  • Providence Health & Services
  • Scott and White Hospital & Clinic
  • Stony Brook University
  • Thomas Jefferson University
  • Royal University Hospital Foundation
  • University of California, Los Angeles
  • University of Florida
  • University of Maryland
  • University of Oklahoma
  • University of Southern California
  • Washington University School of Medicine
Principal Investigator: David F Kallmes, MD Mayo Clinic
Mayo Clinic
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP